The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2024 and forecasted to 2033
The anemia and other blood disorder drugs market has experienced robust growth in recent years, and this upward trend is set to continue. From $11.13 billion in 2023, the market is projected to reach $11.91 billion in 2024, showcasing a Compound Annual Growth Rate (CAGR) of 7.0%. Factors contributing to this growth in the historic period include disease prevalence, global health initiatives, an aging population, pharmaceutical innovation, and increased patient awareness.
Current Market Scenario
- Anticipated CAGR of 6.8% will drive the market to $15.49 billion by 2028.
- Growth in the forecast period attributed to emerging markets, global demographics, and economic factors.
- Major trends include research and development, technological advances, biologics and targeted therapies, gene therapies, telemedicine and remote monitoring, orphan drug designations, and mergers and acquisitions.
Rising Anemia Prevalence Fuels Growth In The Anemia And Blood Disorder Drugs Market
- Increasing prevalence of anemia globally is a key driver.
- Unhealthy lifestyles, changing dietary habits, and heightened stress levels contribute to rising anemia cases.
- Anemia is notably prevalent in the elderly population (> 65 years), reaching a rate of around 17%.
- Anemia ranks as the 8th leading cause of disease among women and the young population.
- Major companies driving the market include Amgen Inc., GlaxoSmithKline PLC, Akebia Therapeutics Inc., and others.
View More On The Anemia And Other Blood Disorder Drugs Market Report 2024 – https://www.thebusinessresearchcompany.com/report/anemia-and-other-blood-disorder-drugs-global-market-report
Increasing Focus On Developing Novel Medications
- Major companies are intensifying efforts to introduce novel medications for a competitive edge.
- Novel medications represent significant advancements or new approaches in treating medical conditions.
- Bristol-Myers Squibb’s Reblozyl, approved by the FDA for anemia in adults with lower-risk myelodysplastic syndromes, showcases a groundbreaking approach.
- The COMMANDS study demonstrates Reblozyl’s superiority over traditional treatments.
Pfizer’s Acquisition Of Global Blood Therapeutics Enhances Drug Portfolio
- In October 2022, Pfizer acquired Global Blood Therapeutics Inc., expanding its anemia and blood disorder drug portfolio.
- This strategic move enhances Pfizer’s position in developing potential best-in-class treatments for sickle cell disease.
- The acquisition underscores the industry’s dynamic landscape with major players seeking strategic partnerships and acquisitions.
Market Segmentation
- The anemia and other blood disorder drugs market is segmented based on various criteria:
- Type: Iron Deficiency Anemia, Chronic Kidney Disease Anemia, Sickle Cell Anemia, Aplastic Anemia
- Route of Administration: Oral, Injectable
- Distribution Channel: Hospitals Pharmacy, Online Pharmacy, Pharmacy
Regional Dynamics: North America Leading, Middle East Emerging
- North America emerged as the largest region in the market in 2023.
- The Middle East is expected to be the fastest-growing region during the forecast period, showcasing the global nature of the market.
Conclusion
The anemia and blood disorder drugs market is evolving dynamically, driven by increasing disease prevalence, pharmaceutical innovations, and strategic advancements by major players. As the industry focuses on novel medications and embraces technological advancements, the future holds promise for groundbreaking treatments. With a diverse range of segments and a global footprint, stakeholders must stay agile and adaptive to navigate the complexities of this expanding market successfully.
Request A Sample Of The Global Anemia And Other Blood Disorder Drugs Market Report 2024:
https://www.thebusinessresearchcompany.com/sample_request?id=2465&type=smp
